ArticleThe journal of vascular access2026
Addressing infection in totally implantable venous access ports: An ex vivo study on bacterial transfer and the Forsvall Port needle design.
Article in The journal of vascular access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTotally implantable venous access ports (TIVAPs) are essential for administering chemotherapeutic drugs and nutritional support, but carry a risk of infectious complications. We hypothesized that the design of the current port needle (Huber) could facilitate the collection of bacteria from the skin during puncture, potentially introducing them into TIVAPs and causing infections. This study examines bacterial transfer via needles during TIVAP access and proposes a novel needle design to reduce the risk of infection.
methodsA novel needle, the Forsvall Port needle, was developed with a closed tip to reduce bacterial transmission inside the needle during tissue and port penetration. In a randomized ex vivo setting, human skin samples covered in physiological levels of
resultsThe Forsvall Port needle reduced average bacterial transfer by 87.0% (95% CI: 77.8%-92.4%,
conclusionThe Forsvall Port needle significantly reduces bacterial transfer into TIVAPs, which could potentially decrease TIVAP-related infections. This study demonstrates a strong association between needle design and bacterial transfer during TIVAP access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.